Table 3 Hazard of eGFR decline of 40% from baseline eGFR within 1 year from the onset of systemic therapy.

Age at treatment

Median (IQR)

63.0 (55.0–71.0)

1.01 (0.99v1.03, p = 0.379)

1.01 (0.99–1.04, p = 0.228)

1.01 (0.99–1.03, p = 0.380)

Nephrectomy prior to systemic therapy

Yes

153

-

-

-

No

204

0.87 (0.56–1.34, p = 0.517)

0.90 (0.57–1.43, p = 0.663)

1.22 (0.71–2.12, p = 0.470)

Sex

Male

227

-

-

-

Female

130

0.97 (0.62–1.53, p = 0.896)

0.99 (0.63–1.56, p = 0.966)

0.91 (0.54–1.53, p = 0.720)

Average eGFR < 60 prior to systemic therapy

Yes

96

-

-

-

No

261

1.08 (0.66–1.77, p = 0.762)

1.28 (0.75–2.16, p = 0.363)

0.94 (0.54–1.63, p = 0.840)

Diabetes

No

307

-

-

-

Yes

50

1.77 (1.04–3.01, p = 0.037)

1.76 (1.03–3.01, p = 0.040)

2.01 (1.11–3.62, p = 0.021)

Metastatic cancer

No

238

-

-

-

Yes

119

0.70 (0.43–1.15, p = 0.158)

0.72 (0.43–1.22, p = 0.225)

0.87 (0.49–1.55, p = 0.640)